Måndag 2 Juni | 17:18:38 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-24 08:00 Kvartalsrapport 2025-Q3
2025-08-27 08:00 Kvartalsrapport 2025-Q2
2025-05-08 - Kvartalsrapport 2025-Q1
2025-05-06 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2025-05-05 - Årsstämma
2025-04-14 - Extra Bolagsstämma 2025
2025-02-21 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-16 - Kvartalsrapport 2024-Q1
2024-05-03 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2024-05-02 - Årsstämma
2024-02-26 - Bokslutskommuniké 2023
2024-02-22 - Extra Bolagsstämma 2024
2023-11-30 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-05-05 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2023-05-04 - Årsstämma
2023-02-17 - Bokslutskommuniké 2022
2022-10-28 - Kvartalsrapport 2022-Q3
2022-07-22 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2022-05-05 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-10-29 - Kvartalsrapport 2021-Q3
2021-08-13 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2021-05-06 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-26 - Bokslutskommuniké 2020
2020-11-13 - Kvartalsrapport 2020-Q3
2020-09-22 - Extra Bolagsstämma 2020
2020-08-21 - Kvartalsrapport 2020-Q2
2020-06-22 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2020-06-18 - Årsstämma
2020-05-14 - Årsstämma
2020-05-13 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-15 - Kvartalsrapport 2019-Q3
2019-08-23 - Kvartalsrapport 2019-Q2
2019-06-18 - Extra Bolagsstämma 2019
2019-05-17 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2019-05-16 - Årsstämma
2019-05-14 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-24 - Kvartalsrapport 2018-Q2
2018-05-25 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2018-05-14 - Kvartalsrapport 2018-Q1
2018-04-03 - Extra Bolagsstämma 2018
2018-02-28 - Bokslutskommuniké 2017
2017-11-13 - Kvartalsrapport 2017-Q3
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-19 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2017-05-18 - Årsstämma
2017-05-18 - Kvartalsrapport 2017-Q1
2017-03-07 - Kapitalmarknadsdag 2017
2017-02-27 - Bokslutskommuniké 2016
2016-11-21 - Kvartalsrapport 2016-Q3
2016-08-22 - Kvartalsrapport 2016-Q2
2016-05-27 - X-dag ordinarie utdelning XBRANE 0.00 SEK
2016-05-27 - Kvartalsrapport 2016-Q1
2016-05-26 - Årsstämma
2016-02-18 - Bokslutskommuniké 2015
2015-10-23 - Kvartalsrapport 2015-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Xbrane Biopharma är verksamt inom bioteknikbranschen och fokuserar på utveckling av biosimilars och biologiska läkemedel. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Produkterna används vid behandling utav prostatacancer och endometrios, samt vid sällsynta och allvarliga ögonsjukdomar. Xbrane Biopharma grundades 2008 och har sitt huvudkontor i Solna.
2025-05-05 18:00:00

The annual general meeting 2025 (the "AGM") of Xbrane Biopharma AB ("Xbrane" or the "Company") was held today on 5 May 2025 and the following resolutions were passed by the meeting.

Adoption of the income statement and the balance sheet

The AGM resolved to adopt the income statement and the balance sheet in Xbrane and the consolidated income statement and the consolidated balance sheet.

Allocation of profit

The AGM resolved not to pay any dividend to the shareholders and that the previously accrued profits, including the share premium account and year result would be carried forward.

Discharge from liability

The board of directors and the managing director were discharged from liability for the financial year 2024.

Election of the board of directors and auditor and remuneration

The AGM resolved, in accordance with the nomination committee's proposal, that the board of directors shall comprise five directors. It was also resolved that the number of auditors shall be one registered audit firm.

It was resolved, in accordance with the nomination committee's proposal, that the remuneration is to be SEK 2,483,000 in total, including remuneration for committee work (SEK 2,437,800 previous year), and shall be paid to the board of directors and the members of the established committees in the following amounts:

  • SEK 327,000 (SEK 321,000) for each of the directors and SEK 655,000 (SEK 642,600) to the chairman;
  • SEK 52,000 (SEK 51,000) for each of the members of the remuneration committee and SEK 104,000 (SEK 102,000) to the chairman of the committee; and
  • SEK 78,000 (SEK 76,500) for each of the members of the audit committee and SEK 156,000 (SEK 153,000) to the chairman of the committee.

It was further resolved that the auditor shall be entitled to a fee in accordance with approved invoice.

The AGM resolved, in accordance with the nomination committee's proposal, to re-elect the directors Eva Nilsagård, Mats Thorén, Anders Tullgren, Kirsti Gjellan and Kristoffer Bissessar. Anders Tullgren was re-elected as chairman of the board.

PricewaterhouseCoopers AB was re-elected as the Company's auditor in accordance with the nomination committee's proposal. PricewaterhouseCoopers AB had announced that the authorized auditor Magnus Lagerberg continues as main responsible auditor.

Adoption of principles for the nomination committee

The AGM resolved, in accordance with the nomination committee's proposal, to adopt principles for the nomination committee to apply until further notice.

Approval of the remuneration report

The AGM resolved not to approve the remuneration report for the financial year 2024. The board of directors will provide a report in the next report on remuneration on how any comments have been taken into account.

Adoption of guidelines for remuneration to senior executives

The AGM resolved, in accordance with the board of directors' proposal, to adopt guidelines for remuneration to senior executives to apply until further notice.

Authorization for the board of directors to issue shares, convertibles and/or warrants

The board of directors resolved, prior to the AGM, to withdraw the proposal for authorization due to the fact that the preliminary outcome of the resolution was not supported with the required majority.

For detailed terms regarding the resolutions at the AGM as described above, please refer to the notice and the complete proposals which are available on the Company's website, www.xbrane.com.

[infoga eventuell boilerplate]